Orexo AB (publ) (ORXOY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in SEKTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 664 | 565 | 624 | 639 | 590 | 26 | - | 19 |
| Operating profit | SEK m | -346 | - | ||||||
| Net profit | SEK m | -84 | -223 | -178 | -128 | -203 | -129 | - | -339 |
| EPS reported | SEK | -3.74 | - | ||||||
| Operating cashflow per share | SEK | 4.98 | - | ||||||
| Capex per share | SEK | 0.00 | - | ||||||
| FCF per share | SEK | 4.98 | - | ||||||
| Free cash flow | SEK m | 173 | - | ||||||
| Net debt | SEK m | -428 | - | ||||||
| Book value equity | SEK m | 489 | - | ||||||
| Book value per share | SEK | 14.13 | - | ||||||
| Number of shares | m | 34.63 | - | ||||||
| DPS (TTM paid) | SEK | 0.00 | - |
Financial summary
Financials in SEKTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.70 | - | ||||||
| P/S LTM | x | 32.00 | - | ||||||
| P/FCF LTM | x | 4.81 | - | ||||||
| EV/EBITDA LTM | x | -1.44 | - | ||||||
| EV/Sales LTM | x | 15.84 | - | ||||||
| Earnings Yield LTM | % | -15.60% | - | ||||||
| FCF Yield | % | +20.79% | - | ||||||
| Quality | |||||||||
| ROE | % | -26.46% | - | ||||||
| ROIC | % | -34.84% | - | ||||||
| Operating margin | % | -13.34% | - | ||||||
| Gross margin | % | -2.13% | - | ||||||
| FCF/Sales | % | +665.38% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -95.60% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | 0.35 | - | ||||||
| Net Debt/EBITDA | x | 1.47 | - | ||||||
| EBIT/Net interest | x | -6.90 | - | ||||||
| Net debt/market cap | % | +58.15% | - | ||||||
| Net debt/Equity | x | -0.87 | - | ||||||
| Gross debt/equity | x | 1.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free